{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:56:34Z","timestamp":1778216194100,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T00:00:00Z","timestamp":1270684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A series of new Mannich bases of<jats:italic>N<\/jats:italic>\u2010[(4\u2010arylpiperazin\u20101\u2010yl)\u2010methyl]\u20103\u2010(chlorophenyl)\u2010pyrrolidine\u20102,5\u2010diones<jats:bold>10\u201323<\/jats:bold>have been synthesized and evaluated for their anticonvulsant activity in maximum electroshock (MES) and subcutaneous pentylenetetrazole (<jats:italic>sc<\/jats:italic>PTZ) seizure threshold tests. Their neurotoxicity was determined using a rotorod screen. Several molecules showed a promising anticonvulsant profile especially in the MES\u2010test. In this model of seizures, the most active were<jats:italic>N<\/jats:italic>\u2010[{4\u2010(4\u2010chlorophenyl)\u2010piperazin\u20101\u2010yl}\u2010methyl]\u20103\u2010(3\u2010chlorophenyl)\u2010pyrrolidine\u20102,5\u2010dione<jats:bold>16<\/jats:bold>and<jats:italic>N<\/jats:italic>\u2010[{4\u2010(3\u2010trifluoromethylphenyl)\u2010piperazin\u20101\u2010yl}\u2010methyl]\u20103\u2010(3\u2010chlorophenyl)\u2010pyrrolidine\u20102,5\u2010dione<jats:bold>17<\/jats:bold>with ED<jats:sub>50<\/jats:sub>values of 21.4 mg\/kg and 28.83 mg\/kg, respectively. Selected derivatives<jats:bold>10<\/jats:bold>,<jats:bold>14<\/jats:bold>, and<jats:bold>16<\/jats:bold>were tested in the psychomotor seizure 6\u2010Hz test from which<jats:italic>N<\/jats:italic>\u2010[{4\u2010(2\u2010chlorophenyl)\u2010piperazin\u20101\u2010yl}\u2010methyl]\u20103\u2010(2\u2010chlorophenyl)\u2010pyrrolidine\u20102,5\u2010dione<jats:bold>10<\/jats:bold>revealed the highest protection with an ED<jats:sub>50<\/jats:sub>of 78 mg\/kg. Compounds<jats:bold>10<\/jats:bold>,<jats:bold>12<\/jats:bold>, and<jats:bold>17<\/jats:bold>were also tested in the pilocarpine\u2010induced status PIPS test. Furthermore,<jats:bold>17<\/jats:bold>was examined in the hippocampal kindling screen after<jats:italic>i.\u00a0p.<\/jats:italic>administration to rats.<\/jats:p>","DOI":"10.1002\/ardp.200900250","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T12:23:49Z","timestamp":1270729429000},"page":"333-341","source":"Crossref","is-referenced-by-count":29,"title":["Synthesis and Anticonvulsant Properties of New Mannich Bases Derived from 3\u2010Aryl\u2010pyrrolidine\u20102,5\u2010diones. Part 1"],"prefix":"10.1002","volume":"343","author":[{"given":"Jolanta","family":"Obniska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Kopytko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Zag\u00f3rska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Chlebek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.63.1.815"},{"key":"e_1_2_1_3_2","unstructured":"O. J.Namara inThe Pharmacological Basis of Therapeutics(Eds.: J. G. Hardman L. E. Limbird A. G. Gilman) McGraw\u2010Hill International Edition New York2001 Chapter 21."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00063-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb01523.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.09.012"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.07.010"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm030913e"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00154a022"},{"key":"e_1_2_1_10_2","unstructured":"A.Camerman N.Camerman inAntiepileptic Drugs: Mechanisms of Action(Eds.: G. H. Glaser J. K. Penry D. M. Woodbury) Raven Press New York1980 Chapter 7."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-1280(00)00364-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-827X(03)00187-3"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.05.020"},{"key":"e_1_2_1_14_2","first-page":"639","volume":"66","author":"Obniska J.","year":"2009","journal-title":"Acta Polon. Pharm. \u2013 Drug Res."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja01154a126"},{"key":"e_1_2_1_16_2","first-page":"223","volume":"55","author":"Obniska J.","year":"1998","journal-title":"Acta Polon. Pharm. \u2013 Drug Res."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s7.10.x"},{"key":"e_1_2_1_18_2","unstructured":"H. S.White J. H.Woodhead K. S.Wilcox J. P.Stables H. J.Kupferberg H. H.Wolf inAntiepileptic Drugs(Eds.: R. H. Levy R. H. Mattson B. S. Meldrum E. Perucca) Lippincott Philadelphia PA2002 Chapter 3."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(69)90128-9"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00302-3"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1978.tb04507.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05815.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030460322"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91050-2"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-3565(25)05160-2","volume":"107","author":"Brown W. C.","year":"1953","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.04504.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2005.12.041"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm050283b"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9603025"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fardp.200900250","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.200900250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:08:48Z","timestamp":1740002928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.200900250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1002\/ardp.200900250"],"URL":"https:\/\/doi.org\/10.1002\/ardp.200900250","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"value":"0365-6233","type":"print"},{"value":"1521-4184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}